Dyskinesia matters
Cenci, M. Angela LU
; Riggare, Sara
; Pahwa, Rajesh
; Eidelberg, David
and Hauser, Robert A.
(2020)
In Movement Disorders
35(3).
p.392-396
- Abstract
Levodopa-induced dyskinesia (LID) represents a significant source of discomfort for people with Parkinson's disease (PD). It negatively affects quality of life, it is associated with both motor and nonmotor fluctuations, and it brings an increased risk of disability, balance problems, and falls. Although the prevalence of severe LID appears to be lower than in previous eras (likely owing to a more conservative use of oral levodopa), we have not yet found a way to prevent the development of this complication. Advanced surgical therapies, such as deep brain stimulation, ameliorate LID, but only a minority of PD patients qualify for these interventions. Although some have argued that PD patients would rather be ON with dyskinesia than OFF,... (More)
Levodopa-induced dyskinesia (LID) represents a significant source of discomfort for people with Parkinson's disease (PD). It negatively affects quality of life, it is associated with both motor and nonmotor fluctuations, and it brings an increased risk of disability, balance problems, and falls. Although the prevalence of severe LID appears to be lower than in previous eras (likely owing to a more conservative use of oral levodopa), we have not yet found a way to prevent the development of this complication. Advanced surgical therapies, such as deep brain stimulation, ameliorate LID, but only a minority of PD patients qualify for these interventions. Although some have argued that PD patients would rather be ON with dyskinesia than OFF, the deeper truth is that patients would very much prefer to be ON without dyskinesia. As researchers and clinicians, we should aspire to make that goal a reality. To this end, translational research on LID is to be encouraged and persistently pursued.
(Less)
- author
- Cenci, M. Angela
LU
; Riggare, Sara
; Pahwa, Rajesh
; Eidelberg, David
and Hauser, Robert A.
- organization
- publishing date
- 2020-03
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- animal models, basal ganglia, drug development, pathophysiology, therapy complications
- in
- Movement Disorders
- volume
- 35
- issue
- 3
- pages
- 5 pages
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- scopus:85077145241
- pmid:31872501
- ISSN
- 0885-3185
- DOI
- 10.1002/mds.27959
- language
- English
- LU publication?
- yes
- id
- 431b19ef-08c6-4b7a-95c6-2da60d8cac13
- date added to LUP
- 2020-01-17 12:05:12
- date last changed
- 2024-04-17 02:46:45
@article{431b19ef-08c6-4b7a-95c6-2da60d8cac13,
abstract = {{<p>Levodopa-induced dyskinesia (LID) represents a significant source of discomfort for people with Parkinson's disease (PD). It negatively affects quality of life, it is associated with both motor and nonmotor fluctuations, and it brings an increased risk of disability, balance problems, and falls. Although the prevalence of severe LID appears to be lower than in previous eras (likely owing to a more conservative use of oral levodopa), we have not yet found a way to prevent the development of this complication. Advanced surgical therapies, such as deep brain stimulation, ameliorate LID, but only a minority of PD patients qualify for these interventions. Although some have argued that PD patients would rather be ON with dyskinesia than OFF, the deeper truth is that patients would very much prefer to be ON without dyskinesia. As researchers and clinicians, we should aspire to make that goal a reality. To this end, translational research on LID is to be encouraged and persistently pursued.</p>}},
author = {{Cenci, M. Angela and Riggare, Sara and Pahwa, Rajesh and Eidelberg, David and Hauser, Robert A.}},
issn = {{0885-3185}},
keywords = {{animal models; basal ganglia; drug development; pathophysiology; therapy complications}},
language = {{eng}},
number = {{3}},
pages = {{392--396}},
publisher = {{John Wiley & Sons Inc.}},
series = {{Movement Disorders}},
title = {{Dyskinesia matters}},
url = {{http://dx.doi.org/10.1002/mds.27959}},
doi = {{10.1002/mds.27959}},
volume = {{35}},
year = {{2020}},
}